TheraVet SA (ALVET.PA)
EUR 0.11
(-0.46%)
EUR 0.11
(-0.46%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 7.53 Million EUR | -20.71% |
| 2022 | 9.5 Million EUR | -17.03% |
| 2021 | 11.45 Million EUR | 124.07% |
| 2020 | 5.11 Million EUR | 144.78% |
| 2019 | 2.08 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 7.14 Million EUR | -5.13% |
| 2024 Q2 | 7.14 Million EUR | 0.0% |
| 2023 Q4 | 7.53 Million EUR | 0.0% |
| 2023 Q2 | 7.95 Million EUR | 0.0% |
| 2023 Q1 | 7.95 Million EUR | -16.24% |
| 2023 FY | 7.53 Million EUR | -20.71% |
| 2023 Q3 | 7.53 Million EUR | -5.33% |
| 2022 Q1 | 10.29 Million EUR | -10.09% |
| 2022 Q4 | 9.5 Million EUR | 0.0% |
| 2022 Q3 | 9.5 Million EUR | -7.72% |
| 2022 Q2 | 10.29 Million EUR | 0.0% |
| 2022 FY | 9.5 Million EUR | -17.03% |
| 2021 Q4 | 11.45 Million EUR | 0.0% |
| 2021 Q1 | 11.63 Million EUR | 127.64% |
| 2021 Q2 | 11.63 Million EUR | 0.0% |
| 2021 Q3 | 11.45 Million EUR | -1.57% |
| 2021 FY | 11.45 Million EUR | 124.07% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 FY | 5.11 Million EUR | 144.78% |
| 2020 Q3 | 5.11 Million EUR | 18.26% |
| 2020 Q4 | 5.11 Million EUR | 0.0% |
| 2020 Q2 | 4.32 Million EUR | 0.0% |
| 2019 FY | 2.08 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | 48.782% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 97.696% |
| Adocia SA | 24.95 Million EUR | 69.81% |
| Aelis Farma SA | 26.28 Million EUR | 71.332% |
| Biophytis S.A. | 11.93 Million EUR | 36.878% |
| Advicenne S.A. | 12.4 Million EUR | 39.275% |
| genOway Société anonyme | 31.84 Million EUR | 76.339% |
| IntegraGen SA | 8 Million EUR | 5.827% |
| Medesis Pharma S.A. | 1.92 Million EUR | -291.115% |
| Neovacs S.A. | 47.53 Million EUR | 84.15% |
| NFL Biosciences SA | 3.97 Million EUR | -89.748% |
| Plant Advanced Technologies SA | 14.91 Million EUR | 49.479% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -101.085% |
| Sensorion SA | 46.49 Million EUR | 83.795% |
| Theranexus Société Anonyme | 7.23 Million EUR | -4.096% |
| TME Pharma N.V. | 2.49 Million EUR | -202.456% |
| Valbiotis SA | 33.24 Million EUR | 77.339% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 78.641% |
| argenx SE | 4.11 Billion EUR | 99.817% |
| BioSenic S.A. | 9.55 Million EUR | 21.182% |
| Celyad Oncology SA | 16.28 Million EUR | 53.727% |
| DBV Technologies S.A. | 165.65 Million USD | 95.452% |
| Galapagos NV | 4.35 Billion EUR | 99.827% |
| Genfit S.A. | 173.87 Million EUR | 95.667% |
| GeNeuro SA | 6.31 Million EUR | -19.346% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 84.199% |
| Innate Pharma S.A. | 184.19 Million EUR | 95.91% |
| Inventiva S.A. | 69.13 Million EUR | 89.103% |
| MaaT Pharma SA | 42.93 Million EUR | 82.45% |
| MedinCell S.A. | 36.94 Million EUR | 79.609% |
| Nanobiotix S.A. | 93.89 Million EUR | 91.976% |
| Onward Medical N.V. | 43.62 Million EUR | 82.731% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 92.952% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 90.801% |
| Oxurion NV | 6.55 Million EUR | -15.026% |
| Pharming Group N.V. | 426.33 Million EUR | 98.233% |
| Poxel S.A. | 4.82 Million EUR | -56.214% |
| GenSight Biologics S.A. | 9.08 Million EUR | 17.088% |
| Transgene SA | 45.21 Million EUR | 83.338% |
| Financière de Tubize SA | 1.92 Billion EUR | 99.608% |
| UCB SA | 15.53 Billion EUR | 99.952% |
| Valneva SE | 469.39 Million EUR | 98.395% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | 75.561% |